摘要
目的分析辅助性T细胞(TH)1/TH2标志性细胞因子与晚期肺腺癌化疗近远期疗效的关联性。方法选取2021年1月至2023年12月江苏省徐州市中医院收治的82例晚期肺腺癌患者为研究对象,均给予培美曲塞+顺铂或卡铂治疗,21 d为1个周期,连续治疗3个周期。比较不同近期临床疗效者化疗前及化疗3个周期后血清γ干扰素(IFN-γ)、白细胞介素(IL)-2、IL-4、IL-10变化及不良反应发生情况,并记录化疗后2年生存与死亡者化疗3个周期后血清IFN-γ、IL-2、IL-4、IL-10差异。结果82例晚期肺腺癌患者均完成3个周期的化疗,其中完全缓解(CR)1例,部分缓解(PR)34例,疾病稳定(SD)28例,疾病进展(PD)19例,晚期肺腺癌患者化疗3个周期后血清IFN-γ、IL-2均高于本组化疗前,血清IL-4、IL-10均低于本组化疗前,差异有统计学意义(P<0.05);CR+PR患者化疗后血清IFN-γ、IL-2高于SD+PD者,差异有统计学意义(P<0.05),血清IL-4、IL-10低于SD+PD者,差异有统计学意义(P<0.05)。CR+PR患者与SD+PD患者的化疗期间不良反应总发生率比较,差异无统计学意义(P>0.05)。42例获得随访终点的晚期肺腺癌患者中死亡8例(19.05%),生存34例(80.95%),化疗后2年死亡者化疗3个周期血清IFN-γ、IL-2低于生存者,差异有统计学意义(P<0.05),血清IL-4、IL-10高于生存者,差异有统计学意义(P<0.05)。结论TH1/TH2平衡不仅与晚期肺腺癌患者化疗近期疗效有关,也与患者远期预后生存情况有关。
Objective To analyze the association between helper T cell(TH)1/TH2 marker cytokines and short-term and long-term efficacy of chemotherapy for advanced lung adenocarcinoma.Methods A total of 82 patients with advanced lung adenocarcinoma admitted in Xuzhou Hospital of TCM from January 2021 to December 2023 were selected as the study subjects.All patients were treated with Pemetrexed+Cisplatin or Carboplatin and were treated for 3 consecutive cycles by taking 21 days as a cycle.The changes of serum interferon-γ(IFN-γ),interleukin(IL)-2,IL-4 and IL-10 and occurrence of adverse reactions were compared among patients with different short-term clinical efficacies before chemotherapy and after 3 cycles of chemotherapy.The differences in serum IFN-γ,IL-2,IL-4 and IL-10 after 3 cycles of chemotherapy were recorded in survivors and dead person at 2 years after chemotherapy.Results All 82 patients with advanced lung adenocarcinoma completed 3 cycles of chemotherapy,including 1 case of complete response(CR),34 cases of partial response(PR),28 cases of stable disease(SD)and 19 cases of progress disease(PD).Serum IFN-γand IL-2 in patients with advanced lung adenocarcinoma after 3 cycles of chemotherapy were enhanced compared with those before chemotherapy,while serum IL-4 and IL-10 were lower than before chemotherapy,with statistical significances(P<0.05).After chemotherapy,serum IFN-γand IL-2 in CR+PR patients were higher than those in SD+PD patients,while serum IL-4 and IL-10 were lower than those in SD+PD patients,with statistical significances(P<0.05).There was no significant difference in the total incidence rates of adverse reactions during chemotherapy between CR+PR patients and SD+PD patients(P>0.05).Among the 42 patients with advanced lung adenocarcinoma who obtained follow-up endpoints,8 cases(19.05%)died and 34 cases(80.95%)survived.Serum IFN-γand IL-2 of dead person at 2 years after chemotherapy were lower than those of the survivors after 3 cycles of chemotherapy,while serum IL-4 and IL-10 were higher than those of the survivors,with statistical significances(P<0.05).Conclusion TH1/TH2 balance is not only related to the short-term efficacy of chemotherapy,but also related to the long-term prognosis survival of patients with advanced lung adenocarcinoma.
作者
张晴
李彩红
ZHANG Qing;LI Caihong(Department of Pathology,Xuzhou Hospital of TCM,Jiangsu Province,Xuzhou221000,China;Department of Oncology Radiotherapy,the Second Affiliated Hospital of Xuzhou Medical University,Jiangsu Province,Xuzhou221000,China)
出处
《中国当代医药》
CAS
2024年第26期52-55,共4页
China Modern Medicine
